CAM-DR is a mechanism in which MM cells escape the cytotoxic effects of anticancer therapy through adhesive interactions with BMSCs and/or ECM components using integrin family adhesion molecules (i.e., CD138/syndecan-1, Vascular Cell Adhesion Molecule-1/VCAM-1, Very Late Activation Antigen/VLA4/α4β1, VLA-5/α5β1, αvβ3 and β7 integrins) [105]. This evidence concerns the gene VCAM1 and Miyoshi myopathy.